Who to call at Sinopia Biosciences, and when
Fundz watches for the moments Sinopia Biosciences starts buying, and tells you who to reach.
- An alert the day Sinopia Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sinopia Biosciences, from your own LinkedIn network
Sinopia Biosciences Receives $2.5M NIH SBIR Phase II Grant for AI-Powered Metabolomics Platform Development
San DiegoBiotechnologyTherapeuticsDescription
Sinopia Biosciences, a San Diego-based biotechnology company, has been awarded a $2.5 million Small Business Innovation Research (SBIR) Phase II grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The grant will support the development and validation of an AI-powered metabolomics foundation model designed to integrate data across different experimental platforms and analytical methods. Under the award, Sinopia will expand its proprietary LEADS® platform using diverse datasets, expand drug perturbation profiling, and evaluate its ability to identify novel therapeutic targets and compounds in preclinical disease models.
Related People
Sinopia Biosciences signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.